Details of 'innovation pass' scheme announced

摘要

NHS patients in England with very rare conditions are to be given access to new medicines not yet appraised by the National Institute for Health and Clinical Excellence. Pharmaceutical companies will be able to apply to a new expert advisory group for an "innovation pass" to allow a licensed drug - which might benefit patients with rare or very rare conditions - to be prescribed through the NHS for a maximum of three years.